FDA Declines To Approve Expanded Use of Dynavax’s Hepatitis B Vaccine In Hemodialysis Patients
Latest regulatory update from Dynavax on HEPLISAV-B vaccine regimen for adults on hemodialysis, with FDA's Complete Response Letter.
Nurix Therapeutics Upcoming Oral Presentation Of Data From Ongoing Clinical Trial Of NX-5948, A Selective BTK Degrader, At EHA2024 June 13 – 16, 2024, In Madrid, Spain
Overall response rate of 70% observed in 10 evaluable heavily pretreated CLL patients Data showcase deepening clinical responses with longer time on therapy in CLL patients including patients with resistance
Kymera Therapeutics Present’s Clinical Data From The Ongoing Phase 1 Trial Of STAT3 Degrader KT-333 At EHA Annual Meeting June 13-16, 2024, In Madrid, Spain
Abstract released today highlights safety, pharmacodynamic and clinical response data collected through February 6, 2024 cut-off date Updated data to be presented at the European Hematology Association (EHA) Annual
Celularity’s Published In ‘Journal For ImmunoTherapy Of Cancer’ Reveals Placental Circulating T Cells For CAR-T Therapy
Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that the Journal
Scilex Holding Announce Final Court Approval Settlement Agreement With Takeda Pharmaceuticals To Resolve The Paragraph IV Patent Infringement Lawsuit
Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute
GE HealthCare, Medis Medical Imaging Collaborate To Focus On Non-Invasive Coronary Assessments To Help Advance Precision Care In Treatment Of Coronary Artery Disease
Collaboration seeks to advance precision care by providing an alternative, non-invasive approach to the assessment of coronary physiology.Both companies will focus on the integration of Medis QFR into GE HealthCare's
CENTOGENE And Evotec Announce Discovery Of New Molecule To Treat Gaucher Disease
CENTOGENE to receive license fee providing Evotec with R&D license to complete next phase of pre-clinical researchCompanies amend existing drug discovery partnership for Evotec to lead continued development. Upon
Fortress Biotech Doses First Paitent In Multi-Center Phase 2 Study Of Triplex For Control Of Cytomegalovirus In Patients Undergoing Liver Transplantation
Helocyte, a majority-owned subsidiary of Fortress Biotech, is developing Triplex for the prevention and treatment of cytomegalovirus in multiple transplant indications, as well as HIV Clinical trial funded by a
Neurocrine Biosciences Presents Data At ECE 2024, The CAHtalyst Program In Congenital Adrenal Hyperplasia And Study Data For Modified-Release Hydrocortisone In Primary Adrenal Insufficiency And CAH
- CAHtalyst™ Phase 3 Baseline Characteristics Highlight Limitations of Current CAH Treatment Paradigm in Children, Adolescents and Adults- Phase 2 Study for Modified-Release Hydrocortisone in Adults with Adrenal
Novo Nordisk’s Wegovy Delivers: Long-Term Study Shows Sustained Weight Loss As Drugmaker Tries To Woo Insurers And Governments
The data could potentially bolster Novo's case for Wegovy as it attempts to convince insurers and governments to cover the cost of the drug.